Mitoxantrone: Benefits and risks in multiple sclerosis patients

V. Martinelli, M. Radaelli, L. Straffi, M. Rodegher, G. Comi

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Mitoxantrone (MTX) is a synthetic antineoplastic cytotoxic drug, active both on proliferative and non-proliferative cells. The efficacy of MTX has been suggested by many open-label or observational studies and demonstrated in four randomized controlled clinical trials (RCTs). It is indicated for reducing neurological disability and the frequency of clinical relapses in patients with progressive relapsing and worsening relapsing-remitting MS patients. The short-term most frequent adverse events observed in RCTs have been nausea/vomiting, alopecia, an increased risk of urinary and respiratory tract infections, phlebitis, transitory leukopenia, amenorrhea in female patients and infertility. However, the most serious risks of the drug are represented by potential cardiotoxicity and leukaemia, whose incidence seems to be higher than previously reported. Therefore, all potential serious adverse events should be carefully considered against the potential relevant benefits of MTX treatment on every single MS patient.

Original languageEnglish
JournalNeurological Sciences
Volume30
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2009

Fingerprint

Mitoxantrone
Multiple Sclerosis
Randomized Controlled Trials
Female Infertility
Phlebitis
Alopecia
Amenorrhea
Leukopenia
Urinary Tract Infections
Respiratory Tract Infections
Antineoplastic Agents
Nausea
Vomiting
Observational Studies
Leukemia
Recurrence
Incidence
Pharmaceutical Preparations
Therapeutics

Keywords

  • Adverse events
  • Leukaemia
  • Mitoxantrone
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Mitoxantrone : Benefits and risks in multiple sclerosis patients. / Martinelli, V.; Radaelli, M.; Straffi, L.; Rodegher, M.; Comi, G.

In: Neurological Sciences, Vol. 30, No. SUPPL. 2, 2009.

Research output: Contribution to journalArticle

@article{e8111d142eff42c8a73f34f4639c7b8e,
title = "Mitoxantrone: Benefits and risks in multiple sclerosis patients",
abstract = "Mitoxantrone (MTX) is a synthetic antineoplastic cytotoxic drug, active both on proliferative and non-proliferative cells. The efficacy of MTX has been suggested by many open-label or observational studies and demonstrated in four randomized controlled clinical trials (RCTs). It is indicated for reducing neurological disability and the frequency of clinical relapses in patients with progressive relapsing and worsening relapsing-remitting MS patients. The short-term most frequent adverse events observed in RCTs have been nausea/vomiting, alopecia, an increased risk of urinary and respiratory tract infections, phlebitis, transitory leukopenia, amenorrhea in female patients and infertility. However, the most serious risks of the drug are represented by potential cardiotoxicity and leukaemia, whose incidence seems to be higher than previously reported. Therefore, all potential serious adverse events should be carefully considered against the potential relevant benefits of MTX treatment on every single MS patient.",
keywords = "Adverse events, Leukaemia, Mitoxantrone, Multiple sclerosis",
author = "V. Martinelli and M. Radaelli and L. Straffi and M. Rodegher and G. Comi",
year = "2009",
doi = "10.1007/s10072-009-0142-7",
language = "English",
volume = "30",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Mitoxantrone

T2 - Benefits and risks in multiple sclerosis patients

AU - Martinelli, V.

AU - Radaelli, M.

AU - Straffi, L.

AU - Rodegher, M.

AU - Comi, G.

PY - 2009

Y1 - 2009

N2 - Mitoxantrone (MTX) is a synthetic antineoplastic cytotoxic drug, active both on proliferative and non-proliferative cells. The efficacy of MTX has been suggested by many open-label or observational studies and demonstrated in four randomized controlled clinical trials (RCTs). It is indicated for reducing neurological disability and the frequency of clinical relapses in patients with progressive relapsing and worsening relapsing-remitting MS patients. The short-term most frequent adverse events observed in RCTs have been nausea/vomiting, alopecia, an increased risk of urinary and respiratory tract infections, phlebitis, transitory leukopenia, amenorrhea in female patients and infertility. However, the most serious risks of the drug are represented by potential cardiotoxicity and leukaemia, whose incidence seems to be higher than previously reported. Therefore, all potential serious adverse events should be carefully considered against the potential relevant benefits of MTX treatment on every single MS patient.

AB - Mitoxantrone (MTX) is a synthetic antineoplastic cytotoxic drug, active both on proliferative and non-proliferative cells. The efficacy of MTX has been suggested by many open-label or observational studies and demonstrated in four randomized controlled clinical trials (RCTs). It is indicated for reducing neurological disability and the frequency of clinical relapses in patients with progressive relapsing and worsening relapsing-remitting MS patients. The short-term most frequent adverse events observed in RCTs have been nausea/vomiting, alopecia, an increased risk of urinary and respiratory tract infections, phlebitis, transitory leukopenia, amenorrhea in female patients and infertility. However, the most serious risks of the drug are represented by potential cardiotoxicity and leukaemia, whose incidence seems to be higher than previously reported. Therefore, all potential serious adverse events should be carefully considered against the potential relevant benefits of MTX treatment on every single MS patient.

KW - Adverse events

KW - Leukaemia

KW - Mitoxantrone

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=74049140477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049140477&partnerID=8YFLogxK

U2 - 10.1007/s10072-009-0142-7

DO - 10.1007/s10072-009-0142-7

M3 - Article

C2 - 19882368

AN - SCOPUS:74049140477

VL - 30

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -